OGEN .625 0.75 MG — DIN 02089793
ESTROPIPATE : 0.75 MG · PFIZER CANADA ULC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is OGEN .625?
OGEN .625 0.75 MG contains ESTROPIPATE : 0.75 MG. It is listed in the Health Canada Drug Product Database under DIN 02089793, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 24-Aug-2012. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is OGEN .625 used for?
Treatment of menopausal and post-menopausal symptoms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Estrone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Estrone, across 6 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SEARCHLIGHT PHARMA INC | 1 | 1 | ESTRAGYN VAGINAL CREAM | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 0 | OGEN .625, OGEN 1.25, OGEN 2.5 | No marketed DIN |
| DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. | 2 | 0 | OESTRILIN CONES VAGINAUX, OESTRILIN CREME VAGINALE 1MG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.75 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Not explicitly detailed in provided text (mentions bottles/containers in general sections). |
| Storage | Not explicitly detailed in provided text (standard summary table/storage section missing specific temperature). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Estrone |
|---|---|
| ATC code | G03CA07 |
| AHFS class | 68:16.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02089793 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2089793 |
| Brand name | OGEN .625 |
| Generic / active ingredient | ESTROPIPATE : 0.75 MG |
| Market authorization holder | PFIZER CANADA ULC |
| Health Canada schedule | Prescription |
| ATC code | G03CA07 |
| ATC anatomical main group | G — Genito-urinary system and sex hormones |
| ATC therapeutic subgroup | G03CA |
| Current status | CANCELLED POST MARKET |
| Status date | 24-Aug-2012 |
| Original market date | 1994-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Given cyclically (21-25 days on, 5-7 days off). Women with intact uteri must take an appropriate dosage of progestin to prevent endometrial hyperplasia/carcinoma. Use lowest effective dose.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Liver dysfunction; estrogen-dependent neoplasia; breast cancer history; endometrial hyperplasia; undiagnosed genital bleeding; pregnancy; arterial/venous thromboembolic disease; classical migraine.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Should not be used for cardiovascular prevention. Increased risk of endometrial carcinoma if used without progestin in intact uteri.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ESTRAGYN VAGINAL CREAM | 0.1 % | CREAM | SEARCHLIGHT PHARMA INC | MARKETED | 00727369 |
| OESTRILIN CONES VAGINAUX | .25 MG | SUPPOSITORY | DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. | CANCELLED POST MARKET | 00006211 |
| OESTRILIN CREME VAGINALE 1MG | 1 MG | CREAM | DESBERGERS LTÉE, DIVISION OF TECHNILAB INC. | CANCELLED POST MARKET | 00006149 |
| OGEN 1.25 | 1.5 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | 02089769 |
| OGEN 2.5 | 3.0 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | 02089777 |
2 · Same class — other molecules in ATC G03CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Estradiol | CLIMARA 100 · CLIMARA 25 · CLIMARA 50 · CLIMARA 75 · +31 more | 51 | 22 | Yes |
| Conjugated Estrogens | APO-CONEST TAB 0.3MG · APO-CONEST TAB 0.625MG · APO-CONEST TAB 0.9MG · APO-CONEST TAB 1.25MG · +15 more | 33 | 4 | Yes |
| Estrone | ESTRAGYN VAGINAL CREAM · OESTRILIN CONES VAGINAUX · OESTRILIN CREME VAGINALE 1MG · OGEN .625 · +2 more | 6 | 1 | Yes |
| Ethinylestradiol | ESTINYL TAB 0.05MG · ESTINYL TAB 0.5MG · ESTINYL TABLETS 0.02 MG. | 3 | 0 | Not in Canada |
| Natural And Semisynthetic Estrogens, Plain | ESTRAGYN · NEO ESTRONE TAB 1.25MG | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC G03C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| G03CC | Conjugated Estrogens And Bazedoxifene | 1 | 1 |
| G03CX | Tibolone | 1 | 1 |
| G03CB | Dienestrol · Diethylstilbestrol | 4 | 0 |
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| DUAVIVE | CONJUGATED ESTROGENS 0.45 MG; BAZEDOXIFENE (BAZEDOXIFENE ACETATE) 20 MG | PFIZER CANADA ULC | MARKETED | 02432854 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.